|
Volumn 13, Issue 2, 2008, Pages 83-85
|
Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics
|
Author keywords
[No Author keywords available]
|
Indexed keywords
5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER;
BIOLOGICAL MARKER;
CYCLIN DEPENDENT KINASE;
CYCLIN DEPENDENT KINASE 10;
ERLOTINIB;
EVEROLIMUS;
GEFITINIB;
LAPATINIB;
MITOGEN ACTIVATED PROTEIN KINASE;
N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;
RAPAMYCIN;
TAMOXIFEN;
TEMSIROLIMUS;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
BREAST CANCER;
CANCER PATIENT;
CELL CYCLE ARREST;
CELL CYCLE G1 PHASE;
CYCLIN DEPENDENT KINASE 10 GENE;
DRUG SENSITIVITY;
FUNCTIONAL GENOMICS;
GENE;
GENE EXPRESSION;
GENE SILENCING;
HORMONAL THERAPY;
HUMAN;
ONCOGENE NEU;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
PROMOTER REGION;
RAF1 GENE;
RNA INTERFERENCE;
SHORT SURVEY;
|
EID: 38549087008
PISSN: 15356108
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ccr.2008.01.021 Document Type: Short Survey |
Times cited : (10)
|
References (12)
|